Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

172
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
172

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fatigue after pediatric bone sarcoma: prevalence and associated factors in pediatric and adult patients and survivors after treatment.

Journal of cancer survivorship : research and practice·2026
Same author

A multi‑country evaluation of healthcare professionals' experiences with the PanCareFollowUp training package to implement person-centred care in childhood cancer survivorship care: A PanCareFollowUp study.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same author

Characteristics and Outcomes of Adolescents (15-18 Years) with Chronic Myelogenous Leukemia (CML) in Chronic Phase: The Experience of the International Registry of Childhood CML.

Cancers·2026
Same author

Systemic Treatment of Advanced Chordoma With Molecular Targeted Therapies: A Large Multicentre European Retrospective Case Series.

Cancer reports (Hoboken, N.J.)·2026
Same author

Predicting Clinical Sensitivities of PDGFRA Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatment.

Cancer research communications·2026
Same author

Deep Learning Predicts Mutations and Outcomes in Gastrointestinal Stromal Tumors from Whole-Slide Images.

Cancer research·2026

Related Experiment Video

Updated: Jul 13, 2025

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

12.5K

Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial.

Raphael Koch1, Lianne Haveman2, Ruth Ladenstein3

  • 1Institute of Biostatistics and Clinical Research, University of Muenster, Germany.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|October 16, 2023
PubMed
Summary

Zoledronic acid (ZOL) maintenance therapy did not improve event-free survival (EFS) or overall survival (OS) in standard-risk Ewing sarcoma (EWS) patients. ZOL also led to increased renal, neurologic, and gastrointestinal toxicities.

More Related Videos

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

3.7K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.5K

Related Experiment Videos

Last Updated: Jul 13, 2025

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

12.5K
A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

3.7K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.5K

Area of Science:

  • Pediatric Oncology
  • Bone Sarcomas
  • Clinical Trials

Background:

  • Ewing sarcoma (EWS) is a rare bone cancer primarily affecting children and young adults.
  • Standard treatment involves intensive chemotherapy and surgery or radiation.
  • Maintenance therapy aims to prevent relapse, but its role in standard-risk EWS requires further investigation.

Purpose of the Study:

  • To evaluate the efficacy of zoledronic acid (ZOL) as maintenance therapy in standard-risk localized EWS.
  • To compare event-free survival (EFS) and overall survival (OS) between patients receiving ZOL and those not receiving add-on therapy.
  • To assess the safety and tolerability of ZOL maintenance therapy in this patient population.

Main Methods:

  • Phase III, open-label, prospective, multicenter, randomized trial (Ewing 2008R1) involving 284 patients across 12 countries.
  • Patients received induction and consolidation chemotherapy, with ZOL initiated during consolidation.
  • Randomization was stratified by tumor site; an adaptive design was employed.

Main Results:

  • No significant difference in EFS (HR 0.74, P=0.27) or OS between the ZOL and no add-on groups.
  • Three-year EFS rates were 84.0% (ZOL) vs. 81.7% (no add-on).
  • ZOL group experienced significantly more renal, neurologic, and gastrointestinal toxicities, including severe renal events.

Conclusions:

  • Zoledronic acid maintenance therapy offers no additional benefit for standard-risk localized EWS.
  • The observed increase in toxicity outweighs any potential, unproven advantages.
  • Current treatment protocols for standard-risk EWS should not include ZOL maintenance.